Publications by authors named "Mark Tawa"

Claim this Profile
I
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
Michael J Palte, Angela Wehr, Mark Tawa, Kristopher Perkin, Richard Leigh-Pemberton

Adv Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Héctor R Guzmán, Mark Tawa, Zhong Zhang, Pasut Ratanabanangkoon, Paul Shaw

J Pharm Sci· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance comparison of a co-crystal of carbamazepine with marketed product.
Magali B Hickey, Matthew L Peterson, Lisa A Scoppettuolo, Sherry L Morrisette, Anna Vetter, Mark D Tawa

Eur J Pharm Biopharm· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does alpha-fluorination affect the structural trans-influence and kinetic trans-effect of an alkyl ligand? Molecular structures of Pd(TMEDA)(CH(3))(R(F)) and a kinetic study of the trans to cis isomerization of Pt(TMEDA)(CH(3))(2)I(R(F)) [R(F) = CF(2)CF(3), CFHCF(3), CH(2)CF(3)].
Russell P Hughes, Monique A Meyer, Mark D Tawa, Antony J Ward, Alex Williamson

Inorg Chem· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis